Artemis Investment Management Llp Increased Axogen Inc (NASDAQ:AXGN) Stake by $14.51 Million

August 12, 2018 - By Mary Markley

AxoGen, Inc. (NASDAQ:AXGN) Logo

Artemis Investment Management Llp increased its stake in Axogen Inc (NASDAQ:AXGN) by 153.67% based on its latest 2018Q2 regulatory filing with the SEC. Artemis Investment Management Llp bought 290,254 shares as the company’s stock rose 53.73% while stock markets declined. The institutional investor held 479,136 shares of the health care company at the end of 2018Q2, valued at $24.07 million, up from 188,882 at the end of the previous reported quarter. Artemis Investment Management Llp who had been investing in Axogen Inc for a number of months, seems to be bullish on the $1.47 billion market cap company. The stock decreased 2.41% or $0.95 during the last trading session, reaching $38.45. About 286,386 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 194.48% since August 13, 2017 and is uptrending. It has outperformed by 181.91% the S&P500.

Artemis Investment Management Llp, which manages about $7.33B US Long portfolio, decreased its stake in Altria Group Inc (NYSE:MO) by 336,596 shares to 6,330 shares, valued at $360,000 in 2018Q2, according to the filing. It also reduced its holding in Lyondellbasell Industries N (NYSE:LYB) by 162,530 shares in the quarter, leaving it with 303,894 shares, and cut its stake in Broadcom Ltd ().

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 4 analysts covering AxoGen (NASDAQ:AXGN), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 6 analyst reports since March 1, 2018 according to SRatingsIntel. As per Tuesday, June 26, the company rating was maintained by Leerink Swann. The stock of AxoGen, Inc. (NASDAQ:AXGN) earned “Market Outperform” rating by JMP Securities on Tuesday, May 1. The firm has “Market Outperform” rating by JMP Securities given on Thursday, March 1. The rating was maintained by Cantor Fitzgerald on Tuesday, May 1 with “Overweight”. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Buy” rating given on Friday, March 2 by Lake Street. Cantor Fitzgerald maintained AxoGen, Inc. (NASDAQ:AXGN) rating on Wednesday, February 28. Cantor Fitzgerald has “Buy” rating and $37.0 target.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.47 billion. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

More important recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Fool.com which released: “Here’s Why AxoGen, Inc. Fell as Much as 18.6% Today” on August 02, 2018, also Nasdaq.com published article titled: “AxoGen, Inc. Reports 2018 Second Quarter Financial Results”, Globenewswire.com published: “AxoGen, Inc. to Present at Canaccord Genuity Growth Conference” on July 25, 2018. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) was released by: 247Wallst.com and their article: “5 Incredible Stocks to Buy Now That Wall Street Ignores” with publication date: August 09, 2018.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.